UK regulatory news for peptide medicine — MHRA decisions, NHS policy changes and what new rules mean for patients and prescribers.
In June 2026, a wave of Daily Mail warnings about unlicensed retatrutide triggered an unusually fierce public debate. Readers pushed back hard in patient communities and online discussion groups dedicated to weight loss medicines. Some called the coverage scaremongering. Others said the safety warnings were long overdue. The argument itself reveals something important: demand for…
Demand for obesity medicines in the UK has reached a tipping point. According to Reuters, millions of Britons are actively considering weight loss treatment, but the healthcare infrastructure to support them — on the NHS and in the private sector — is struggling to keep pace. Experts are warning that without serious investment in access,…
A major new survey from the Food Foundation, published in June 2026, has found that millions of UK adults have either used or seriously considered weight loss drugs. The findings paint a striking picture of a country where demand for obesity medicines is surging — but where the healthcare system is struggling to keep up….
If you are taking Mounjaro or Ozempic, there is something important you may not have considered. Driving while impaired by medication side effects is illegal in the UK — and weight loss jabs are no exception. (LadBible UK, 21 May 2026) Motoring experts have issued a warning that Mounjaro and Ozempic users face fines of…
In January 2026, the Medicines and Healthcare products Regulatory Agency — the MHRA, which is the UK equivalent of a medicines safety watchdog — updated its official product information for all GLP-1 and dual GLP-1/GIP weight loss injections. That includes semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro…
In January 2026, the Medicines and Healthcare products Regulatory Agency — the MHRA, which is the UK equivalent of a medicines watchdog — quietly updated the official product information for every GLP-1 weight loss drug available in Britain. [GOV.UK (MHRA), 29 January 2026] That list includes semaglutide (the active ingredient in Ozempic and Wegovy) and…
If you have been waiting for Mounjaro on the NHS, April 2026 brought the most significant shift yet. NHS England confirmed that tirzepatide — the active ingredient in Mounjaro — will now feature in the GP contract for 2026 to 2027. That means GPs in England are, for the first time, formally supported to prescribe…
If you are taking Mounjaro or Ozempic, you already know the drill on nausea and tiredness. What you may not know is that those same side effects could make it illegal for you to drive. And if you have not declared them to the DVLA, you could face a fine of up to £1,000 [LadBible…